Analyst firm Bernstein has raised its price target for GSK to £28.25 from £26.30, citing a new proprietary model that suggests the drugmaker's HIV franchise can keep growing for longer than previously expected. The upgrade is based on a deep-dive analysis that, for the first time, incorporates GSK's long-acting HIV medicines—injectable treatments that require less frequent dosing—and projects their impact through 2040.
Why the HIV Franchise Looks More Durable
For pharmaceutical companies, patent exclusivity is the lifeblood of profitability. Once a drug's patents expire, generic competitors typically enter the market and drive prices down, a phenomenon known as the "patent cliff." Bernstein's new model argues that GSK's long-acting HIV portfolio, particularly a candidate called VH184, could enjoy a longer patent runway than earlier products. That would push the patent cliff further into the future, giving GSK more years of relatively protected sales.
Bernstein now expects GSK to slowly gain US market share in HIV from rival Gilead. The firm raised its adjusted earnings-per-share forecasts for 2026 through 2036 by as much as 25%, reflecting the potential for steadier cash flows from a more durable HIV business.
What It Means for Investors
For everyday investors, this analysis highlights how small changes in patent life can matter more than small changes in next year's sales. By treating more of GSK's HIV revenue as longer-lived, Bernstein is effectively boosting the valuation of the entire franchise—even if near-term demand doesn't change much.
The flip side is that the story becomes more sensitive to legal and clinical milestones. The strength of VH184's exclusivity will depend on regulatory approvals, patent challenges, and clinical trial results. Any setback could quickly erode the projected gains.
GSK's stock has been under pressure in recent months amid broader market volatility, but the Bernstein upgrade could provide a catalyst. The new price target implies roughly 7% upside from the previous target, though actual returns will hinge on how the HIV pipeline develops.
Broader Market Context
The upgrade comes as markets digest mixed signals from the broader economy. Recent data showed US inflation meeting forecasts and GDP growth revised higher, which helped lift the TSX and other indices. Meanwhile, energy stocks have crept higher on rising oil prices, and gold has rebounded above $4,000 as the dollar eased. In the tech sector, AI-related forecasts from Micron and Qualcomm have lifted futures and European tech stocks, while China's Z.ai plans a Shanghai listing after its open-source AI model rivaled US giants.
For GSK, the focus remains on its pipeline and patent strategy. Investors will watch for clinical trial updates on VH184 and any legal developments around its patent protection. If Bernstein's model proves accurate, GSK could deliver stronger earnings growth than the market currently expects.
The Bottom Line
Bernstein's upgrade is a bet that GSK's HIV franchise has more staying power than the market prices in. The long-acting drug portfolio could extend the company's competitive advantage and push back the patent cliff, supporting higher earnings for years to come. But the thesis depends on execution: VH184 must clear regulatory hurdles and fend off generic challengers. For now, the analyst firm is willing to pay up for that potential.
